II. Pathophysiology
III. Epidemiology
- Children
- Most commonly affects ages 1 to 11 years old (peak age 1 to 4 years old)
- More rapid spread associated with Atopic Dermatitis
- Adolescents and Adults
- Sexually Transmitted Infection
- Significant outbreaks associated with HIV
IV. Symptoms
- Mild Pruritus may be present (often asymptomatic)
V. Signs
- Characteristics
- Discrete single or clustered lesions (<30 in group)
- Raised, small firm dome-shaped Papules 3-5 mm diameter
- Skin Colored or pearly white
- Waxy-appearing
- Central punctate umbilication
- Distribution
- Face
- Trunk
- Lower Abdomen
- Extremities
- Rarely affects palms and soles
- Pubis, inner thigh and genitalia (adults with STD)
- Mucosa may be involved
- Extensive involvement in HIV
VI. Labs: Microscopy of Incision and Drainage material
- Staining will show molluscum bodies
- Wright's Stain
- Giemsa Stain
- Gram Stain
VII. Management
-
General
- Treatment is optional as these resolve on their own (over as long as 2-4 years)
- Avoid painful procedures for this benign, self-limited condition (especially in children)
- If treatment is desired, consider Aldara instead of Cryotherapy
- Treat those with Atopic Dermatitis or other underlying cause to prevent spread
- Red and inflamed lesions are in the process of resolution
- Do not treat these lesions with cyrotherapy or Topical Medications
- Expect spontaneous resolution soon after inflammation appears
- Treatment is optional as these resolve on their own (over as long as 2-4 years)
-
Cryotherapy
- Consider Topical Anesthetic pretreatment in children
- Apply under Occlusion 15 to 30 minutes before
- Products
- EMLA
- ELA-Max
- Consider Topical Anesthetic pretreatment in children
-
Electrodessication and Curettage (not recommended due to scarring risk)
- Consider following curettage with application of:
- Iodine
- Trichloroacetic Acid 30%
- Consider following curettage with application of:
-
Vesicant Application
- Keratolytic Agents
- Cantharidin
- YCanth
- Single use applicator of Cantharidin FDA approved for age >2 years (in 2023, approaches $700/applicator)
- Applied by medical provider every 3 weeks for 4 visits
- Clearance of molluscum in 3 months (NNT 3)
- (2023) Presc Lett 30(10): 58-9
- YCanth
- Imiquimod 5% cream (Aldara; not FDA approved for molluscum)
- Preferred option by many dermatologists, although evidence of significant efficacy is lacking
- Apply to skin lesion for 6-10 hours, then wash off
- Apply 3 times weekly for 4 to 16 weeks
- Do not use on mucous membranes
-
Berdazimer (Zelsuvmi)
- Applied daily for up to 12 weeks
- HIV patients
- Cidofovir has been used in advanced molluscum
VIII. Prevention
- Molluscum contagiousum is contagious with direct skin contact
- No school restrictions
- Wrestling participation criteria
- Active lesions must be covered with clothing or secure waterproof bandage
IX. Course
- Often spontaneously resolves without treatment
- After 1 year: 50% of cases persist
- After 2 years: 13% of cases persist
- Some lesions may persist untreated as long as 2-4 years)
- Conditions associated with severe Molluscum
- HIV Infection
- Other immunocompromising conditions
- Atopic Dermatitis
X. Complications
- Scarring may occur
- Infammatory response to lesions (differentiate from secondary infection)
- Local Inflammation (redness, swelling)
- ID Reaction